Then, the evaluation of the feasibility of treating alveolar bone resorption in obese patients with periodontitis with RBP4/visfatin monoclonal antibodies or blockers (such as combining novel drug delivery platforms, like injectable gels or microneedles) lays the foundation for long-term clinical transformation and precise treatment. Here, RBP4 is linked to periodontitis.